| Inavolisib studied in …STUDIED_INderived28 of 28show fewer |
|---|
| → studied in | NCT05646862Phase 3 · recruiting A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07054190Phase 2 · recruiting A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05708235Phase 2 · active not recruiting A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05894239Phase 3 · recruiting A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748208Phase 2 · not yet recruiting A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191499Phase 2/Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04929223Phase 1 · recruiting A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) · 28 trials list this drug (24 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05306041Phase 2 · recruiting Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer · 28 trials list this drug (24 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03424005Phase 1/Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04931342Phase 2 · active not recruiting A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors · 28 trials list this drug (24 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03006172Phase 1 · active not recruiting To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer · 28 trials list this drug (24 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07347600recruiting A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07405801Phase 2 · recruiting A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04589845Phase 2 · active not recruiting Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study · 28 trials list this drug (24 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07368998Phase 2 · recruiting To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802759Phase 1/Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer · 28 trials list this drug (24 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06790693Phase 3 · recruiting A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07287150Phase 2 · recruiting A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer · 28 trials list this drug (24 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05862285Phase 3 · recruiting A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study · 28 trials list this drug (24 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04449874Phase 1 · active not recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation · 28 trials list this drug (24 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06496568Phase 1 · active not recruiting A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers · 28 trials list this drug (24 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07522697Phase 2 · not yet recruiting Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 · 28 trials list this drug (24 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04486352Phase 1/Phase 2 · recruiting A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer · 28 trials list this drug (24 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07323576Phase 2 · withdrawn A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer · 28 trials list this drug (24 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04849364Phase 2 · terminated Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer · 28 trials list this drug (24 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05332561Phase 2 · recruiting Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) · 28 trials list this drug (24 active) | — | — | Early Stage Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04551521Phase 2 · completed CRAFT: The NCT-PMO-1602 Phase II Trial · 28 trials list this drug (24 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04632992Phase 2 · completed A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response · 28 trials list this drug (24 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |